Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent

被引:8
作者
Shang, Chuquan [1 ]
Hassan, Bardes [1 ,2 ]
Haque, Moinul [1 ]
Song, Yuqi [1 ,3 ]
Li, Jing [1 ,4 ]
Liu, Dongzhe [1 ,5 ,6 ]
Lipke, Eva [1 ,7 ]
Chen, Will [1 ]
Giuriato, Sylvie [8 ]
Lai, Raymond [1 ,9 ]
机构
[1] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB T6G 2R3, Canada
[2] Cairo Univ, Fac Vet Med, Dept Pathol, Giza 12211, Egypt
[3] Jilin Univ, Norman Bethune Hlth Sci Ctr, Changchun 130021, Peoples R China
[4] Harbin Med Univ, Coll Basic Med Sci, Elect Microscopy Ctr, Harbin 150080, Peoples R China
[5] Shenzhen Univ Gen Hosp, Dept Hematol & Oncol, Shenzhen 518055, Peoples R China
[6] Harbin Med Univ, Coll Basic Med Sci, Lab Biol & Chem, Harbin 150080, Peoples R China
[7] Albstadt Sigmaringen Univ, Dept Life Sci, D-72488 Sigmaringen, Germany
[8] Univ Toulouse III Paul Sabatier, CRCT, INSERM U1037, CNRS ERL5294, F-31037 Toulouse, France
[9] Univ Alberta, Dept Oncol, Edmonton, AB T6G 2R3, Canada
关键词
autophagy; ALK plus ALCL; cancer stem-like cells; MYC; crizotinib; chloroquine; resistance;
D O I
10.3390/cancers13020181
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Autophagy is a cell survival and recycling mechanism which protects cancer cells upon therapeutic drug treatment. Here we investigated the impact of autophagy inhibition in a cancer of lymphoid origin, namely ALK-positive anaplastic large cell lymphoma (ALK + ALCL). We inhibited autophagy in two distinct cell subsets of ALK + ALCL, one of which we previously shown to possess more stem-like and tumorigenic properties. Our study found that blockage of autophagy in the stem-like subset resulted in marked drug-sensitization to crizotinib, a current therapeutic agent used to treat ALK + ALCL. We also found differential involvement of the Myconcogene in the autophagy process within the two subsets and identified its relative importance to the stem-like population. Our research suggests inhibition of autophagy alongside crizotinib preferentially targets stem-like cells, thus improving crizotinib therapy. Previously it was shown that autophagy contributes to crizotinib resistance in ALK-positive anaplastic large cell lymphoma (ALK + ALCL). We asked if autophagy is equally important in two distinct subsets of ALK + ALCL, namely Reporter Unresponsive (RU) and Reporter Responsive (RR), of which RR cells display stem-like properties. Autophagic flux was assessed with a fluorescence tagged LC3 reporter and immunoblots to detect endogenous LC3 alongside chloroquine, an autophagy inhibitor. The stem-like RR cells displayed significantly higher autophagic response upon crizotinib treatment. Their exaggerated autophagic response is cytoprotective against crizotinib, as inhibition of autophagy using chloroquine or shRNA against BECN1 or ATG7 led to a decrease in their viability. In contrast, autophagy inhibition in RU resulted in minimal changes. Since the differential protein expression of MYC is a regulator of the RU/RR dichotomy and is higher in RR cells, we asked if MYC regulates the autophagy-mediated cytoprotective effect. Inhibition of MYC in RR cells using shRNA significantly blunted crizotinib-induced autophagic response and effectively suppressed this cytoprotective effect. In conclusion, stem-like RR cells respond with rapid and intense autophagic flux which manifests with crizotinib resistance. For the first time, we have highlighted the direct role of MYC in regulating autophagy and its associated chemoresistance phenotype in ALK + ALCL stem-like cells.
引用
收藏
页码:1 / 16
页数:16
相关论文
共 37 条
  • [21] Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing
    Xia, Yuxue
    Zhang, Lu
    He, Wenjuan
    Pan, Huaxiong
    Fang, Jun
    Cui, Guohui
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [22] Treatment of Relapsed and Refractory ALK-Positive Anaplastic Large Cell Lymphoma With ALK-Specific Tyrosine Kinase Inhibitor in Children: A Case Series
    Shen, Diying
    Song, Hua
    Zhang, Jingying
    Liao, Chan
    Wang, Yan
    Fang, Meixin
    Tang, Yongmin
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2022, 44 (01) : E1 - E4
  • [23] Diagnosis of the leukemic phase of ALK-positive anaplastic large cell lymphoma by immunohistochemistry on cell block prepared from peripheral blood buffy coat
    Kundoo, Aditi
    Sethy, Madhusmita
    Sable, Mukund N.
    Mishra, Pritinanda
    Panigrahi, Asuthosh
    Adhya, Amit K.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2020, 63 (04) : 642 - 644
  • [24] An Isolated Cutaneous Relapse in a Known Case of Systemic ALK-Positive Anaplastic Large Cell Lymphoma: A Rare Case Report with Review of Literature
    Shetty, Monisha
    Girisha, Banavasi Shanmukha
    Gowda, Sona C.
    Shetty, Vijith
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2024,
  • [25] CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series
    Ruf, Stephanie
    Hebart, Holger
    Hjalgrim, Lisa Lyngsie
    Kabickova, Edita
    Lang, Peter
    Steinbach, Daniel
    Schwabe, Georg C.
    Woessmann, Wilhelm
    PEDIATRIC BLOOD & CANCER, 2018, 65 (06)
  • [26] Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
    Zdzalik, Daria
    Dymek, Barbara
    Grygielewicz, Paulina
    Gunerka, Pawel
    Bujak, Anna
    Lamparska-Przybysz, Monika
    Wieczorek, Maciej
    Dzwonek, Karolina
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (04) : 589 - 598
  • [27] Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
    Daria Zdzalik
    Barbara Dymek
    Paulina Grygielewicz
    Pawel Gunerka
    Anna Bujak
    Monika Lamparska-Przybysz
    Maciej Wieczorek
    Karolina Dzwonek
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 589 - 598
  • [28] Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement
    Rigaud, Charlotte
    Abbou, Samuel
    Ducasso, Stephane
    Simonin, Mathieu
    Le Mouel, Lou
    Pereira, Victor
    Gourdon, Stephanie
    Lambilliotte, Anne
    Geoerger, Birgit
    Minard-Colin, Veronique
    Brugieres, Laurence
    HAEMATOLOGICA, 2022, 107 (09) : 2255 - 2260
  • [29] MYC-dependent MiR-7-5p regulated apoptosis and autophagy in diffuse large B cell lymphoma by targeting AMBRA1
    Zhang, Cuifen
    Wang, Ke
    Tao, Jiahao
    Zheng, Chuangjie
    Zhai, Linzhu
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2025, 480 (01) : 191 - 202
  • [30] Interim Results of a Study of Comparative Efficiency of the NHL-BFM-90 and CHOEP Programs in Primary Adult Patients of ALK-Positive Anaplastic Large Cell Lymphoma
    Gorenkova, Lilya
    Kravchenko, Sergey
    Klebanova, Elena
    Kovrigina, Alla
    Gemdzhian, Eduard
    Mangasarova, Yana
    Magomedova, Aminat
    Misyurin, Andrey
    Julhakyan, Hunan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S270 - S270